We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Starts Dosing Patients in Oral COVID-19 Drug Trial
Pfizer Starts Dosing Patients in Oral COVID-19 Drug Trial
Pfizer began dosing yesterday in a phase 2/3 study evaluating its oral COVID-19 antiviral PF-07321332 in non-hospitalized symptomatic patients who are not at increased risk of progressing to severe disease.